2025 · 2nd Quarter (Apr 1 - June 30)

CMC PHARMACEUTICALS

Filed by CAPITOL COUNSEL LLC.

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 21, 2025
Income: $40,000.00
Expenses: Not reported
Registrant: CAPITOL COUNSEL LLC
Client: CMC PHARMACEUTICALS
Filing UUID: a526f68f-a3bc-47b1-805e-84ca72d7c55d
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

BUD · Budget/Appropriations

Support for Department of Defense Chemical Biological Defense medical countermeasures pre and post-exposure protection funding.

DEF · Defense

Issues related to the FY26 National Defense Authorization Act and Defense Appropriations.

GOV · Government Issues

Support for Department of Defense Chemical Biological Defense medical countermeasures pre and post-exposure protection policy.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.